Selective profiling of proteins in lung cancer cells from fine-needle aspirates by matrix-assisted laser desorption ionization time-of-flight mass spectrometry

被引:35
作者
Amann, Joseph M.
Chaurand, Pierre
Gonzalez, Adriana
Mobley, James A.
Massion, Pierre P.
Carbone, David P.
Caprioli, Richard M.
机构
[1] Vanderbilt Univ, Dept Med, Div Hematol Oncol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA
[3] Vet Affairs Med Ctr, Dept Canc Biol, Nashville, TN 37212 USA
[4] Vet Affairs Med Ctr, Mass Spectrometry Res Ctr, Nashville, TN 37212 USA
[5] Vet Affairs Med Ctr, Dept Biochem, Nashville, TN 37212 USA
[6] Vet Affairs Med Ctr, Dept Pathol, Nashville, TN 37212 USA
[7] Vet Affairs Med Ctr, Div Allergy Pulm & Crit Care Med, Nashville, TN 37212 USA
关键词
D O I
10.1158/1078-0432.CCR-06-0264
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) has been used to analyze tumor sections and can determine tumor type, nodal involvement, and survival, and shows promise in predicting therapeutic response. Our purpose was to develop a method compatible with MALDI-TOF MS that allows selective analysis of cancer cells in mixed clinical samples such as fine-needle aspirates. Experimental Design: Lung cancer cell lines were cytocentrifuged onto metal-coated, transparent glass slides and used for optimization of fixation, staining, and RBC lysis protocols. Fine-needle aspirates from human tumors and mouse model tumors were used to provide fresh tissue samples for determining the feasibility of this method. Results: The MALDI-TOF MS compatible fixation and staining techniques provided high-resolution cellular morphology, which allowed identification and selective spotting of tumor cells. The RBC lysis step efficiently removed contaminating RBC yielding spectra nearly free from hemoglobin peaks. Protein profiles of fine-needle aspirates were found highly reproducible and similar to the profiles of the tissue from which they were obtained. Using this method, we were able to differentiate between xenograft tumors derived from two different human cell lines, A549 and H460. Conclusion: This procedure results in the production of high-quality, cancer cell-specific protein profiles. This highly reproducible technique could be applied to many other types of mixed clinical samples and has the potential to be very useful in the clinical diagnosis, classification, and, potentially, the individualized treatment of cancer patients.
引用
收藏
页码:5142 / 5150
页数:9
相关论文
共 22 条
  • [1] Automated acoustic matrix deposition for MALDI sample preparation
    Aerni, HR
    Cornett, DS
    Caprioli, RM
    [J]. ANALYTICAL CHEMISTRY, 2006, 78 (03) : 827 - 834
  • [2] Assersohn L, 2002, CLIN CANCER RES, V8, P794
  • [3] Proteomics in diagnostic pathology - Profiling and imaging proteins directly in tissue sections
    Chaurand, P
    Sanders, ME
    Jensen, RA
    Caprioli, RM
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2004, 165 (04) : 1057 - 1068
  • [4] Integrating histology and imaging mass spectrometry
    Chaurand, P
    Schwartz, SA
    Billheimer, D
    Xu, BGJ
    Crecelius, A
    Caprioli, RM
    [J]. ANALYTICAL CHEMISTRY, 2004, 76 (04) : 1145 - 1155
  • [5] Ellis M, 2002, CLIN CANCER RES, V8, P1155
  • [6] Atmospheric pressure matrix-assisted laser desorption/ionization in transmission geometry
    Galicia, MC
    Vertes, A
    Callahan, JH
    [J]. ANALYTICAL CHEMISTRY, 2002, 74 (08) : 1891 - 1895
  • [7] Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring
    Golub, TR
    Slonim, DK
    Tamayo, P
    Huard, C
    Gaasenbeek, M
    Mesirov, JP
    Coller, H
    Loh, ML
    Downing, JR
    Caligiuri, MA
    Bloomfield, CD
    Lander, ES
    [J]. SCIENCE, 1999, 286 (5439) : 531 - 537
  • [8] Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology
    Kristan, KA
    Mann, L
    Cox, K
    Treadway, P
    Iversen, P
    Chen, YF
    Teicher, BA
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (04) : 321 - 327
  • [9] Lim EH, 2003, CLIN CANCER RES, V9, P5980
  • [10] Monitoring the serological proteome: The latest modality in prostate cancer detection
    Mobley, JA
    Lam, YW
    Lau, KM
    Pais, VM
    L'Esperance, JO
    Steadman, B
    Fuster, LMB
    Blute, RD
    Taplin, ME
    Ho, SM
    [J]. JOURNAL OF UROLOGY, 2004, 172 (01) : 331 - 337